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Abstract
Background: In otologic surgery good visualization is paramount, and patients with bleeding diatheses or who
need to be anti-coagulated can present a significant challenge. Here, we determine whether Floseal™, a hemostatic
matrix, is ototoxic in a validated animal model.
Methods: Nine chinchillas housed in the animal care facilities of the Montreal Children’s Hospital Research Institute were
used for the study. After a myringotomy incision was made in each tympanic membrane, baseline auditory brainstem
response measurements were performed at 8, 20, and 25 kHz. In each animal one ear was randomized to receive
Floseal™ to the middle ear cavity, whereas the other ear served as the control and received 0.9% sodium chloride.
Outcome measures included early (day 7) and late (day 30) auditory brainstem response, clinical evidence of facial
nerve or vestibular disturbance and histological evidence of ototoxity.
Results: There was no significant hearing threshold shift on auditory brainstem response across all tested frequencies
for both experimental and control ear. No animals receiving Floseal™ developed facial or vestibular nerve dysfunction
and there was no histological evidence of ototoxicity.
Conclusion: Based on the preliminary ototoxicity assessment on nine chinchillas, transtympanic Floseal™ does not
appear to be ototoxic. More studies are warranted to assess the safety and applicability of the product in humans.
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Background
Floseal™ is a hemostatic matrix consisting of bovine-
derived gelatin matrix and human-derived thrombin
isolated from pooled plasma [1]. The thrombin is recon-
stituted in sodium chloride solution and mixed with the
gelatin matrix prior to application. The high concentra-
tions of human thrombin convert fibrinogen into fibrin
monomers to accelerate clot formation and the gelatin
granules swell to produce a tamponade effect. While it
has been used for nasal and sinus bleeding [2–4] its use
in the middle ear has not been reported.
In otologic surgery good visualization is paramount,
and patients with bleeding diatheses or who need to be
anti-coagulated can present a significant challenge. In
circumstances where traditional hemostatic agents such
as epinephrine, oxymetazoline, or gelfoam are ineffect-
ive, Floseal™ may be an option in ensuring adequate
hemostasis and to complete otologic surgery. The
objective of the present study was to evaluate the
ototoxicity of Floseal™ in a chinchilla animal model.
Methods
Animal care and ethics
The study received approval by the Animal Care
Committee of the McGill University Health Centre
Research Institute and was conducted at the McGill
Auditory Sciences Laboratory in accordance with the
guidelines of the Canadian Council for Animal Care.
Reporting of the animal study was done following the
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ARRIVE guidelines. Nine female chinchillas (C. Laniger,
Ryerson Chinchilla Ranch, OH) with normal baseline
auditory brainstem-evoked response (ABR) thresholds
were included in the study. The animals were housed in
temperature and light (12 h day/night cycle) controlled
rooms with free access to water and commercial food by
the animal care research facilities of the Montreal
Children’s Hospital Research Institute.
Hearing evaluation
Hearing assessment was conducted by measuring auditory
brainstem response (ABR) on Chinchilla anesthetized by
5% Isoflurane and maintained with 3% Isoflurane. Acous-
tic stimuli of 8,000, 20,000, and 25,000 Hz pure tone
bursts were presented to the Chinchilla through insert
earphones starting at 80 dB intensity and decreasing by
5 dB until a threshold was reached. A threshold was
identified when three replicable waves were found. Hear-
ing evaluations were performed at baseline, early (day 7)
and late (day 30) after application of Floseal™.
Transtympanic application of floseal™
A 10 mL syringe of Floseal™ Hemostatic Matrix (Baxter)
was prepared according to product instructions for use
immediately prior to injection.
Each of nine animals had one ear randomized as the
experimental ear, while the contralateral ear served as a
control. An incision in the anterio-inferior quadrant of the
tympanic membrane was made and 0.3–0.7 mL of Floseal™
(until visualization through the tympanic membrane under
the microscope showed that the middle ear was filled) was
introduced into the experimental middle ear via a soft poly-
ethylene tubing catheter. The same volume of 0.9% NaCl
was instilled into the control ears. Examination under
general anesthesia the following day confirmed the pres-
ence of product in the middle ear cavities.
Post-euthanasia middle ear examination and scanning
electron microscopy (SEM)
Thirty days after the application of Floseal™ all animals
were euthanized. The middle ears of all animals were
opened and examined grossly for bony or mucosal
changes. The cochlea were dissected, separated into
apex, middle and base, then fixed in 4% paraformalde-
hyde. Post-fixation staining with osmium tetroxide and
graded dehydration with 30, 50, 70, 80, 90, and 100%
alcohol was performed. Specimens were critical-point
dried using Leica CPD 030, mounted, gold plated, and
viewed using the Hitachi field emission electron micros-
copy (Hitachi S4700, Tokyo, Japan).
Statistical analysis
Early (day 7) and late (day 30) shifts in ABR thresholds
after application of Floseal™ were compared using paired
T-test between the experimental and control ears across
all three frequencies tested (8, 20, 25 kHz). A
P-value ≤ 0.05 was considered statistically significant.
Our sample size was calculated with a minimum ab-
solute difference represented by the mean ABR
threshold difference of 20 dB, a standard deviation of
16 dB, and an alpha of .10. The ears were grouped
depending on the treatment received.
Results
Physical observations
All animals receiving Floseal™ intratympanically remained
in good health until the end of the experiment. No sign of
weight loss, facial paralysis, head tilt or disequilibrium
were present.
ABR Threshold shifts
There was no significant difference in ABR thresholds
before application and at day 7 and day 30 after
application for both control and experimental ears at
all three frequencies tested. The highest threshold
shift was following 30 days of injection in the experi-
mental ear at 20 kHz (11.1 ± 3.4 dB, p = 0.65) and was
not significantly different from the control ear
(10.8 dB, p = 0.87). No significant hearing loss differ-
ence was observed at all frequencies and time points
tested (Table 1).
Gross assessment
After euthanasia and temporal bone dissection revealed
two animals with thickened white effusions in the mid-
dle ear. One animal had both experimental and control
ears affected while the other was only affected in the
experimental ear. For the remaining animals no changes
in the bulla were noted.
Table 1 Mean Hearing Threshold (dB) Differences from Baseline and day 7 and 30 post Injection
Day 7 Day 30
Frequency (in kHz)
8 20 25 8 20 25
Experimental (Floseal™) −8.3 ± 5.3 8.9 ± 3.4 −7.5 ± 3.8 −2.8 ± 3.4 11.1 ± 3.4 −0.3 ± 3.4
Control (PBS) −7.8 ± 5.1 7.5 ± 4.0 −1.9 ± 5.1 −1.1 ± 3.5 10.8 ± 4.3 −0.8 ± 4.9
dB decibels, kHz kilohertz, PBS phosphate buffered saline
Auditory brainstem response (ABR) threshold shifts in the control and experimental ears at 7 and 30 days post-application of Floseal™
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Histology (Scanning electron microscopy)
Three randomly selected pairs of cochlea were observed
under SEM, which revealed no damage to the cochlear
hair cells. The three rows of outer hair cells and the row
of inner hair cells in the Organ of Corti were intact in
both the control and experimental ears (Fig. 1).
Discussion
Bleeding in middle ear surgery can significantly decrease
visibility, potentially preventing successful completion of
surgery. Most commonly, epinephrine or a decongestant
such as oxymetazoline is used for homeostasis in middle
ear surgery, however in cases where these agents are un-
successful alternative options must be considered.
Gelfoam is sometimes used as a packing agent in the
middle ear, however its inability to conform to the spaces
in the middle ear make it of limited use as an important
hemostatic agent. Floseal™ is a commercial hemostatic
agent composed of bovine-derived gelatin matrix and
human-derived thrombin isolated from pooled plasma. It
can be applied on wet, actively bleeding tissues, conforms
to irregular surfaces and has been shown to be more
effective than gelfoam in heparinized patients [5]. After
application of the Floseal matrix, the gelatin particles swell
and tamponade the bleeding as the gelatin matrix-
thrombin composite slows the blood flow and provides
exposure to a high concentration of thrombin, hastening
clot formation [6]. Particularly in conditions where
patients need to be anti-coagulated, such as having a me-
tallic cardiac valve or stent it would be useful to know
whether hemostatic agents such as Floseal™ can safely be
used without causing ototoxicity. There have been reports
questioning the possible ototoxicity of gelatin foam [7],
however there is no clear scientific evidence of this; par-
ticularly when instilled in the middle ear.
Some agents such as gelatin foam have been suspected
of contributing to conductive hearing loss due to
scarring [8–10], however this has never been tested. Flo-
seal™ appears as an acceptable option for hemostasis in
the middle ear and surrounding structures. Our study is
the first to demonstrate that Floseal™ applied to the mid-
dle ear is not ototoxic as evidenced by the ABR results
on days 7 and 30 post-application as well as the electron
microscopy of the cochlea. The non-significant threshold
shifts found in Flosea™ and saline exposed ears likely re-
sulted from an independent factor such as myringo-
sclerosis from myringotomy and catheter manipulation
during injection. Two animals were found to have thick-
ened white effusions in the middle ear during temporal
bone dissection. In one animal it was only in the experi-
mental ear while in the other it was bilateral. Therefore,
effusion occurred in 2 out of 9 ears (22%) receiving Flo-
seal™ and 1 out of 9 control ears (11%). The underlying
factor behind the found effusion is elusive; it could be
associated with the surgical intervention or due to the
presence of Floseal™ in the middle ear. Care should be
taken in the use of Floseal™ in patients with atopy,
particularly in those with a known allergy to gelatin
products as this may lead to a life-threatening anaphyl-
actic reaction [11].
The limitations of this study include the low sample
size. The ototoxicity assessment of the present study was
conducted in only nine animals. Also, although not
evidenced by the physiological testing and histological
analysis, the nature of effusion found in experimental
ears should be further investigated.
Conclusion
Based on the preliminary ototoxicity assessment on nine
chinchillas, transtympanic Floseal™ does not appear to
be ototoxic. More studies are warranted to assess the
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Fig. 1 Scanning electron microscopy showing comparison between
control (a) and experimental (b) histological micrographs
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